Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins

PDA Journal of Pharmaceutical Science and Technology

Volumn 54, Issue 3, 2000, Pages 233-239

  Bhardwaj, Renu ^b   Dorr, Robert T ^b   Blanchard, James ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; MANNITOL; MITOMYCIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; MOUSE; NONHUMAN; PATIENT COMPLIANCE; SKIN NECROSIS; SKIN TOXICITY; SKIN ULCER;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MITOMYCIN; SKIN; SOLUBILITY;

EID: 0033940697     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. J. P. Davignon and J. C. Craddock. "Pharmaceutical aspects of antitumor agents." Pharm. Weekblad. 119, 1144-1150 (1984).
2. K. Csoka, S. Dhar, H. Fridborg, R. Larson and P. Nygren. "Differential activity of Cremophor EL and Paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro." Cancer 79, 1225-1233 (1997).
3. L. Glasser, P. D. Sternglanz, J. Combie, and A. Robinson. "Serum osmolality and its applicability to drug overdose." Amer. J. Clin. Pathol. 60, 695-699 (1973).
4. Anon, Physician's Desk Reference, 46th ed., 1992, Medical Economics Data, Montvale, NJ, pp. 733-734.
5. L. C. Argenta and E. K. Manders. "Mitomycin C extravasation injuries." Cancer 51, 1080-1082 (1983).
6. H. A. Wood and J. M. Ellerhorst-Ryan. "Delayed adverse skin reactions associated with Mitomycin-C administration." Oncology Nursing Forum 11, 14-18 (1984).
7. J. Szejtli. "Cyclodextrins in drug formulations: Part I," Pharm. Technol. 15, 36-44 (1991).
8. D. Duchene, D. Wouessidjewe. "Physicochemical characteristic and pharmaceutical uses of cyclodextrin derivatives, Part I," Pharm. Technol. 14, 26-34 (1990).
9. J. Blanchard and S. Proniuk. "Some important considerations in the use of cyclodextrins." Pharm. Res. 16, 1796-1798 (1999).
10. T. Higuchi and K. A. Connors. "Phase-solubility techniques." Adv. Analyt. Chem. Instrum., Wiley-Interscience, New York, 4, 117-212 (1965).
11. G. Carlsson, B. Gullberg, and L. Hafström. "Estimation of liver tumor volume using different formulas - An experimental study in rats." J. Cancer Res. Clin. Oncol. 105, 20-23 (1983).
12. R. T. Dorr, M. J. Soble, J. D. Liddil and J. H. Keller. "Mitomycin C skin toxicity studies in mice: Reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide." J. Clin. Oncol. 4, 1399-1404 (1986).
13. K. A. Connors and J. A. Mollica, Jr. "Theoretical analysis of comparative studies of complex formation." J. Pharm. Sci. 55, 772-780 (1966).
14. K. A. Connors. "The applications of complexation to drug-delivery systems development." Pharm. Manuf. 2, 22-56 (1985).
15. O. Beckers, J. H. Beijnan, M. J. K. Tank, A. Bult, and W. J. M. Underberg. "Effect of cyclodextrins on the chemical stability of mitomycins in alkaline solution." J. Pharm. Biomed. Anal. 9, 1055-1060 (1991).
16. B. W. Müller and U. Brauns. "Hydroxypropyl-Cyclodextrin derivatives: Influence of average degree of substitution on complexing ability and surface activity." J. Pharm. Sci. 75, 571-572 (1986).
17. S. Proniuk and J. Blanchard, unpublished observations.